Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

AIMS To examine the extent of platelet inhibition by prasugrel vs. clopidogrel in a TRITON-TIMI 38 substudy. METHODS AND RESULTS TRITON-TIMI 38 randomized acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) to prasugrel or standard dose clopidogrel. Selected sites prospectively enrolled TRITON-TIMI 38 patients to evaluate adenosine diphosphate (ADP)-attenuated phosphorylation of platelet vasodilator-stimulated phosphoprotein (VASP) (n = 125 patients) and, in a subset (n = 31 patients), ADP-stimulated platelet aggregation. VASP platelet reactivity index (PRI) was lower in prasugrel-treated patients than in clopidogrel-treated patients at 1-2 h post-PCI (>or=1 h after loading dose) (P < 0.001) and at 30 days (P < 0.001). Maximal platelet aggregation to 20 microM ADP was lower in prasugrel-treated patients than in clopidogrel-treated patients at 1-2 h (P = 0.004) and 30 days (P = 0.03). Results were similar with 5 microM ADP. Thienopyridine hyporesponsiveness, prespecified as VASP PRI >50%, was more frequent in clopidogrel-treated patients than in prasugrel-treated patients at 1-2 h (P < 0.001) and 30 days (P = 0.03). CONCLUSIONS The TRITON-TIMI 38 platelet substudy shows that prasugrel results in greater inhibition of ADP-mediated platelet function in ACS patients than clopidogrel, supporting the hypothesis that greater platelet inhibition leads to a lower incidence of ischaemic events and more bleeding both early and late following PCI.

[1]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[2]  A. Michelson.  P2Y12 Antagonism: Promises and Challenges , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[4]  Reena Gupta.  Atherothrombosis and Coronary Artery Disease , 2005 .

[5]  K. Winters,et al.  Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel , 2007, Journal of cardiovascular pharmacology.

[6]  Atherothrombosis and coronary artery disease , 2005 .

[7]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  M. Furman,et al.  Resistance to antiplatelet drugs , 2006 .

[9]  U. Walter,et al.  CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation , 2003 .

[10]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[11]  A. Michelson,et al.  Clopidogrel linking evaluation of platelet response variability to mechanism of action. , 2005, Journal of the American College of Cardiology.

[12]  A. Siegbahn,et al.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.

[13]  E. Antman,et al.  Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.

[14]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[15]  J. Jakubowski,et al.  Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. , 2005, Seminars in thrombosis and hemostasis.

[16]  A. Siegbahn,et al.  Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. , 2007, European heart journal.

[17]  S. Wiviott.  Clopidogrel response variability, resistance, or both? , 2006, The American journal of cardiology.

[18]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[19]  M. Russo,et al.  Structural myocardial abnormalities in asymptomatic family members with Brugada syndrome and SCN5A gene mutation. , 2009, European heart journal.

[20]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[21]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[22]  P. Barragan,et al.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.

[23]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[24]  K. Winters,et al.  A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry , 2007, Thrombosis and Haemostasis.

[25]  J. Jukema,et al.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. , 2007, American heart journal.

[26]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[27]  R. Becker,et al.  CHAPTER 35 – Atherothrombosis and Coronary Artery Disease , 2007 .

[28]  L. Wallentin,et al.  Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. , 2007, Cardiovascular drug reviews.

[29]  Deepak L. Bhatt,et al.  The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention , 2008, Clinical cardiology.

[30]  Paul J. Harrison,et al.  Measuring antiplatelet drug effects in the laboratory. , 2007, Thrombosis research.

[31]  K. Hagihara,et al.  The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite , 2007, Journal of thrombosis and haemostasis : JTH.